Ian Molk, MD
Cardiology · Edison, NJNPI 1073546636
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,345 of the $3,738 with a category attached, or 89.5%. It is spread thinly across 23 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $959 and has fallen 95.4% since, to $44 in 2025.
Across 156 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$710
- Astellas Pharma US Inc$367
- Johnson & Johnson$321
- Boston Scientific$299
- AstraZeneca$261
- Amgen$243
- plus $2K from 17 others
What the payments were for
- Food & beverage$3,34589%
- Education$39211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 8 | $710 |
| Astellas Pharma US Inc | 6 | $367 |
| Johnson & Johnson | 16 | $321 |
| Boston Scientific | 6 | $299 |
| AstraZeneca | 12 | $261 |
| Amgen | 18 | $243 |
| Amarin Pharma, Inc. | 18 | $228 |
| Boehringer Ingelheim | 15 | $207 |
| Novartis | 13 | $190 |
| Arbor Pharmaceuticals, Inc. | 10 | $156 |
| Impulse Dynamics (USA) Inc. | 2 | $155 |
| Pfizer | 10 | $135 |
| Cvrx, Inc. | 1 | $114 |
| Sanofi-aventis U.S. LLC | 5 | $65 |
| Biotronik Inc. | 2 | $64 |
| Merck | 3 | $45 |
| Novo Nordisk | 3 | $43 |
| Irhythm Technologies, Inc. | 1 | $29 |
| Amryt Pharma Holdings Ltd | 2 | $28 |
| Heartflow, Inc. | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 2 | $22 |
| Bardy Diagnostics, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Watchman$245
- Confirm Rx$226
- OPTIMIZER SMART SYSTEM$138
- HeartMate Touch$133
- XARELTO$125
- AVEIR$124
- FARXIGA$114
- Barostim Neo System$114
How this compares
$3,738 in reported general payments places this provider in the 70th percentile of 31 cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 177 | $203,917 |
| XareltoRivaroxaban | 138 | $144,326 |
| EntrestoSacubitril/Valsartan | 66 | $68,621 |
| BrilintaTicagrelor | 38 | $29,257 |
| Repatha SureclickEvolocumab | 14 | $21,360 |
| JardianceEmpagliflozin | 12 | $20,619 |
| VascepaIcosapent Ethyl | 17 | $14,272 |
| FarxigaDapagliflozin Propanediol | 19 | $13,238 |
| Atorvastatin Calcium | 562 | $6,260 |
| Nebivolol Hcl | 71 | $5,453 |
| Ezetimibe | 180 | $5,174 |
| Valsartan | 112 | $4,620 |
| Metoprolol Succinate | 266 | $3,938 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 104 | $2,964 |
| Rosuvastatin Calcium | 135 | $2,709 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $135 | $203,917177 claims |
| Johnson & JohnsonXarelto | $321 | $144,326138 claims |
| NovartisEntresto | $190 | $68,62166 claims |
| AstraZenecaBrilinta, Farxiga | $261 | $42,49557 claims |
| Boehringer IngelheimJardiance | $207 | $20,61912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 31 cardiology providers in New Jersey.
Other cardiology in Edison
- Ricardo CalvoEdison$5K
- Michael SchwarzRutherford$40K
- Beverly DemchukOcean$12K
- Lei XuBrown Hills$10K
- Sarika SharmaRochelle Park$9K
- Vasant Paul KateBrick$7K
- Pragnesh GadhviUnion City$7K
- Ebrahim IssaTeaneck$5K
- Marc ColmerNeptune$5K
- Tanveer AhmadBrick$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.